viewMGC Pharmaceuticals Ltd

MGC Pharmaceuticals launches new CannEpil® App

MGC Pharmaceuticals Ltd (ASX:MXC) co-founder and MD Roby Zomer speaks to Proactive about the launch of its new CannEpil® app.

The app is designed to collect patient data and provides medical professionals with access to the International Library of Cannabinoids (ILC) as part of its collaboration with Royal Melbourne Institute of Technology (RMIT).

Zomer said: “This will help us to better understand how the medicine is working on the patient and eventually will help us to be more accurate in our clinical studies.”

Data collection on this scale will provide comprehensive information on cannabinoid treatments, driving growth in the industry and will assist the company to tailor future products and ensure their efficacy from early stages of development.

Quick facts: MGC Pharmaceuticals Ltd

Price: 0.024 AUD

Market: ASX
Market Cap: $39.38 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...


MGC Pharma updates on ArtemiC coronavirus study and first-ever THC shipment...

MGC Pharmaceuticals Ltd's (ASX:MXC) Roby Zomer speaks to Proactive's Andrew Scott soon after announcing positive results from a pre-clinical study of ArtemiCTM on rats with no pathological changes or differences between the study groups reported. He also discusses its first-ever shipments of the...

41 minutes ago

2 min read